SLC12A2 and Seizure: A previous study suggested that NKCC1 might be a potential drug target for the treatment of neonatal seizures [12], but recent clinical trials in human infants found severe side effect of NKCC1 blocker bumetanide and limited effect in treating neonatal seizure [13].